Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
about
Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosisNanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.In vitro evaluation of TLR4 agonist activity: formulation effects.A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresisEffectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic miceImmune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.Induction of Strong and Specific Humoral and T-helper 1 Cellular Responses by HBsAg Entrapped in the Methanobrevibacter smithii ArchaeosomesThe TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic MechanismA Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 ActivationInterferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidatesDevelopment of a schistosomiasis vaccine.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activityRehmannia glutinosa polysaccharide liposome as a novel strategy for stimulating an efficient immune response and their effects on dendritic cellsElimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes.Role of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.Old and new adjuvants.IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants.Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.Successes and failures in human tuberculosis vaccine development.The role of toll-like receptor 4 in tumor microenvironment.Protein nanovaccine confers robust immunity against Toxoplasma.Modulation of Immune Responses by Particulate Materials.Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune ResponsesThe TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
P2860
Q26863391-161BCF53-CD69-4AB7-8F1A-9949A2CA7F59Q30274995-68C24D68-3219-4D74-913F-D52AB1BDCE6EQ30359243-26DB3D16-478E-4E8A-8137-0BEB62480274Q30561113-02D7F691-3F79-4F44-A12C-135B33EDC949Q33583613-107B4C3D-8AC8-47C7-ADDD-A4F3F41195D9Q33641234-F050C8B7-6C96-4B73-AD34-4A46B2566778Q33855226-89C15D8F-EEB0-49DE-AE20-C6EF1231A740Q34146613-7D54A097-ECA5-43AD-AFB8-440519E7FFA9Q34474186-7FD61F85-394A-4463-A040-87C8F597CBB4Q35885464-CE405A15-3451-4A4C-9F28-95F122844C2CQ35915755-EDAF6455-5AEC-4081-8E96-49F2B0EB3E2FQ36075279-C9C6CA2C-7C77-48E0-A03A-E7A31C6E367DQ36162709-F002C058-AFA0-4BC7-B8BE-0E3903365BC8Q36303844-D90D8EC6-B52D-4B4F-836A-65421F670430Q36372507-8AE4A0B0-F5E4-4281-85DF-3B19F3B80606Q36909492-8E939CED-79B6-440F-A828-FD63271287D5Q37350747-73B3B909-F844-47CA-917F-9AB90329240EQ37431320-466AB94E-B4CD-4FF8-B22A-9D1DFEDB38B6Q37434381-56A560CE-D471-4D0A-965D-AD2472943065Q37515726-DE529A00-44CF-414A-8DA0-565443A3F66EQ37641418-92C02DF8-D62C-4BB9-8429-D4CC560011A5Q37641676-190D074A-BF61-46BC-BBE0-EA7B693ED639Q38209327-188C18ED-5439-4744-AF0A-DD48EB9EB433Q39012279-F34BB324-D592-4D76-9B05-86DB2B618339Q39049093-8FD57548-654C-4794-9DE8-EA20463993AEQ39451745-F57EFF68-8FEF-4E05-A508-C9D21BC27E5BQ40476014-9C3E31CC-2318-423F-8B68-7DEF9B331BDBQ40513173-CEDB04E7-3C80-4671-A4B0-CAC4BC4ECB2FQ40517477-7AB777E0-71F0-4F10-8D06-38C47C7E0049Q41678523-899F7129-2D26-473B-8E4B-9FDCB9038C03Q41996442-79B838C0-612F-46F7-A92B-1965BB3A796BQ42371680-387EF030-6E51-4CF0-AA48-66801AD781ABQ47102683-8CC44E35-4708-47DF-ABC2-55D963910212Q51336724-BC465F44-68BE-439A-ACFC-446B9DDB4A79Q55436384-3101D5BA-E7BA-48E2-B0F5-542AEE5B1CCAQ55691134-55F93062-8CC8-41F7-BCE9-E9266CD4A389Q56944933-D6C4D063-F2CE-40F4-A833-9F6A8CF4B9A0Q58765317-01893A45-DF6F-42A1-B089-6747012031DC
P2860
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adjuvant formulation structure ...... vaccine against tuberculosis.
@en
Adjuvant formulation structure ...... vaccine against tuberculosis.
@nl
type
label
Adjuvant formulation structure ...... vaccine against tuberculosis.
@en
Adjuvant formulation structure ...... vaccine against tuberculosis.
@nl
prefLabel
Adjuvant formulation structure ...... vaccine against tuberculosis.
@en
Adjuvant formulation structure ...... vaccine against tuberculosis.
@nl
P2093
P2860
P50
P1476
Adjuvant formulation structure ...... vaccine against tuberculosis.
@en
P2093
Elyse Lucas
James J Moon
Rhea N Coler
Sandra J Sivananthan
Susan L Baldwin
Thomas S Vedvick
P2860
P304
P356
10.1016/J.JCONREL.2013.07.030
P407
P577
2013-08-09T00:00:00Z